MAIA Biotechnology Expands U.S. Enrollment in Phase 2 NSCLC Trial After FDA Clearance — MAIA Biotechnology, Inc.

Event summary

FDA cleared MAIA Biotechnology's IND amendment to open U.S. enrollment in the Phase 2 THIO-101 trial for ateganosine in advanced NSCLC.
The trial expansion focuses on third-line (3L) NSCLC patients resistant to prior checkpoint inhibitors and chemotherapy.
MAIA plans to activate up to five U.S. clinical sites for THIO-101 Parts C and D in 2026.
Ateganosine has shown overall survival (OS) beyond two years for eight patients in earlier trial phases.
MAIA is also conducting a pivotal Phase 3 trial (THIO-104) for ateganosine sequenced with a checkpoint inhibitor.

The big picture

MAIA Biotechnology's expansion of the THIO-101 trial into the U.S. marks a critical step in validating ateganosine's potential as a third-line treatment for NSCLC. The FDA's Fast Track designation and Accelerated Approval pathway highlight the unmet need in this patient population, while the ongoing Phase 3 trial (THIO-104) could provide pivotal data for regulatory filings. The company's ability to scale manufacturing and enroll patients will be key to sustaining momentum in this competitive oncology space.

What we're watching

Regulatory Momentum: Whether the FDA's Fast Track designation and Accelerated Approval pathway will accelerate ateganosine's path to market.
Clinical Efficacy: How the expansion data from THIO-101 Parts C and D will compare to earlier phases, particularly in third-line NSCLC.
Execution Risk: The pace at which MAIA can activate additional U.S. clinical sites and enroll patients in the THIO-101 trial.